drugset / Trial / NCT01599234

A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis

NCT01599234

Phase 3 Completed 337 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis

Timeline

Start
2005-03
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified 60 mg Other
Subject Nabiximols Other / unclassified 65 mg Other

Indications